

# Urinary tract symptoms that should be improved to enhance post-operative urinary quality of life in patients treated with low-dose-rate brachytherapy for prostate cancer: An importance–performance analysis

Takayuki Sakurai, MD, PhD<sup>1</sup>, Shigeyuki Takamatsu, MD, PhD<sup>1</sup>, Satoshi Shibata, MD, PhD<sup>1</sup>, Risako Minamikawa, MD<sup>1</sup>, Masahiro Yamazaki, MD<sup>1</sup>, Akihito Okubo, MD<sup>1</sup>, Risa Nagaoka, MD<sup>1</sup>, Tomoyuki Makino, MD, PhD<sup>2</sup>, Renato Naito, MD, PhD<sup>2</sup>, Hiroshi Yaegashi, MD, PhD<sup>2</sup>, Atsushi Mizokami, MD, PhD<sup>2</sup>, Satoshi Kobayashi, MD, PhD<sup>1</sup>

<sup>1</sup>Department of Radiology, Graduate School of Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan, <sup>2</sup>Department of Integrative Cancer Therapy and Urology, Graduate School of Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan

## Abstract

**Purpose:** To evaluate international prostate symptom score and urinary quality of life in patients with prostate cancer who underwent low-dose-rate brachytherapy, and to identify lower urinary tract symptoms that must be improved to enhance post-operative urinary quality of life and factors associated with lower urinary tract symptoms.

**Material and methods:** This study included 193 patients who underwent low-dose-rate brachytherapy alone (145 Gy). Importance–performance analysis was conducted to identify lower urinary tract symptoms that should be prioritized to improve urinary quality of life. Association between lower urinary tract symptom scores and each factor was investigated. Receiver operating characteristic curve analysis was used to evaluate dosimetric parameters related to lower urinary tract symptom score to predict an average score of  $\geq 3$ . Cut-off values were determined.

**Results:** One to nine months post-implantation was a period of significantly increased urinary quality of life scores compared with baseline ( $p < 0.05$  each). The importance–performance analysis conducted for 1–9 months revealed that frequency, nocturia, and weak stream required improvement. Multivariate analysis showed that each lower urinary tract symptom score presented a significant association with its baseline value ( $p < 0.001$  each, positive correlation). Frequency, incomplete emptying, urgency, and straining scores were significantly associated with prostate volume, whereas weak stream and intermittency scores were associated with dose covering 90% of the prostate and dose covering 90% of the urethra, respectively ( $p < 0.05$  each, positive correlations). Cut-off values for these doses were 167.01 Gy and 136.84 Gy, respectively.

**Conclusions:** This study highlights the importance of prioritizing specific lower urinary tract symptoms for improvement in post-operative urinary quality of life, and identifies the associated factors that can help in personalized treatment planning and goal-setting for better patient satisfaction.

J Contemp Brachytherapy 2024; 16, 1: 1–9  
DOI: <https://doi.org/10.5114/jcb.2024.135646>

**Key words:** prostate cancer, low-dose-rate brachytherapy, international prostate symptom score, urinary quality of life, importance–performance analysis, dosimetric factors.

## Purpose

According to the guidelines of the National Comprehensive Cancer Network [1] and the European Association of Urology [2], the recommended standard therapy for low-risk prostate cancer includes low-dose-rate brachytherapy (LDR-BT) alone or external-beam radiation therapy

(EBRT) alone. For intermediate-risk prostate cancer, the guidelines suggest either LDR-BT, EBRT, or a combination of these therapies. However, temporary worsening after LDR-BT in terms of international prostate symptom score (IPSS), a measure of lower urinary tract symptoms (LUTS) [3], and seven-grade urinary quality of life (uQoL), a measure of satisfaction with LUTS [3], has been reported [4–9].

**Address for correspondence:** Takayuki Sakurai, Department of Radiology, Graduate School of Medicine, Kanazawa University, Kanazawa, Ishikawa 920-8641, Japan, phone: +81-76-265-2323, e-mail: [tkyk81@gmail.com](mailto:tkyk81@gmail.com)

Received: 09.12.2023

Accepted: 26.01.2024

Published:

Correlations between IPSS and uQoL after LDR-BT have also been reported [10]. In a previous study, patients who underwent LDR-BT alone were more likely to experience worsening of urinary incontinence and irritative symptoms after 6 months and 1 year when compared with patients who underwent EBRT alone [11]. Therefore, patients must be monitored for worsening of LUTS and decrease in uQoL after undergoing LDR-BT. IPSS consist of seven lower urinary tract symptoms, including incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia. Although the importance of uQoL in patients undergoing LDR-BT for prostate cancer has been established, few reports are available, in which all seven LUTS were associated with uQoL following LDR-BT. Moreover, no study has identified LUTS that must be considered to improve uQoL after LDR-BT.

Importance-performance analysis (IPA), developed by Martilla and James in 1977, helps understand the prioritization of services for improving customer satisfaction [12]. IPA has been used in business domain as well as medical and public health fields, as an approach to enhance patient satisfaction and health [13, 14].

The current study aimed to investigate IPSS and uQoL scores of patients with prostate cancer who underwent LDR-BT alone, and to determine the period during which the uQoL score declined. IPA was performed with the period of uQoL decline to identify LUTS that should be prioritized for improvement in post-operative urinary quality of life. Furthermore, the clinical and dosimetric factors associated with each of these LUTS were investigated.

## Material and methods

### Study design and patients

This retrospective study was approved by the Institutional Review Board of our hospital (approval No.: 2022-321 [114217]), and conducted in accordance with the principles of the Declaration of Helsinki. Between March 2011 and January 2022, 268 patients diagnosed with prostate cancer classified as low-risk or intermediate-risk disease according to D'Amico risk classification underwent LDR-

BT using permanent iodine-125 ( $^{125}\text{I}$ ) seed implantation. Only patients who could be followed for at least 1 year after LDR-BT were included in this analysis.

### LDR-BT protocol


Patients with intermediate-risk prostate cancer or large prostate volume received neoadjuvant hormonal therapy 3–4 months prior to LDR-BT.

Day 0. A previously reported real-time intra-operative planning technique was applied to implant  $^{125}\text{I}$  seeds permanently [15]. Intra-operative real-time peripheral loaded implant technique outlined by Stock *et al.* was used in this study [16]. Seed activity value was 11.0 or 13.1 MBq, and prescribed implantation dose was 145 Gy. Intra-operative planning aimed to maintain the dose covering 90% of the prostate ( $D_{90}$ ) at a level of  $\geq 160$  Gy, the prostate receiving 100% of the dose ( $V_{100}$ ) at  $\geq 95\%$ , the prostate receiving 150% of the dose ( $V_{150}$ ) at  $\leq 60\%$ , the dose covering 30% of the urethral volume ( $uD_{30}$ ) at  $\leq 200$  Gy, and the urethral volume receiving 150% of the dose ( $uV_{150}$ ) at  $\leq 0.0$  cc. The patient was transferred from the operating room to the hospital room post-implantation with urinary catheter in place.

Day 1. Computed tomography (CT) was performed with urinary catheter in place to verify seed placement and presence of hematomas. The urinary catheter was removed if no issue was identified. Administration of  $\alpha 1$ -blocker (0.2 mg/day of tamsulosin, or 8 mg/day of silodosin) was initiated according to clinical protocol. Patients who have been taking an  $\alpha 1$ -blockers prior to implantation were instructed to continue taking them.

Day 2. The patient was discharged.

Day 30. Post-implantation dosimetry was performed using CT and magnetic resonance imaging (MRI) results. CT imaging and MRI fusion was performed, followed by prostate contouring predominantly with MR images. Urethral positioning for post-implantation dosimetry was determined based on CT image acquired on the day after implantation. Urethral contour for post-implantation dosimetry was established as an equilateral triangle of 7 mm on CT image (Figure 1A, B). CT images were used to



**Fig. 1.** Computed tomography (CT) images acquired for post-implantation dosimetry (A). CT image obtained on the day after implantation (B). Urethral region of interest is delineated on CT image for post-implantation dosimetry (A) based on CT image acquired on the day after implantation with an indwelling urethral catheter (B)

identify the implanted seeds, and dosimetric parameters for the prostate and urethra were calculated. Dosimetric parameters investigated included  $D_{90}$ ,  $V_{100}$ ,  $V_{150}$ , the dose covering 5% of the urethral volume ( $uD_5$ ), the dose covering 10% of the urethral volume ( $uD_{10}$ ),  $uD_{30}$ , the dose covering 90% of the urethral volume ( $uD_{90}$ ),  $uV_{150}$ , and the urethral volume receiving 200% of the dose ( $uV_{200}$ ).

### Assessment of LUTS and urinary QoL

LUTS and uQoL scores were assessed using IPSS and the seven-grade uQoL score before implantation, at 1 and 3 months post-implantation, and every 3 months thereafter.

### Importance–performance analysis


In the original IPA, importance and performance are derived *via* customer surveys, where importance indicates the significance of attribute to the customer, and performance is customer satisfaction with the attribute. A two-dimensional matrix-grid is constructed, with importance on the vertical axis and performance on the horizontal axis [12]. After evaluating performance and importance of various attributes, their means are plotted on four quadrants of the matrix-grid. Attributes with low performance but high importance are prioritized for improvement and classified into ‘concentrate here’ quadrant. The other quadrants are ‘keep up the work’, ‘low priority’, and ‘possible overkill’ (Figure 2A). Several modifications have been made to the IPA methodology [17, 18]. One popular modification is the diagonal line model [18–21] that involves adding an iso-priority or iso-rating line, a diagonal line at a 45-degree angle to IPA grid. Bacon reported that the diagonal line model outperformed the original IPA, and strongly recommended its use for IPA [22]. In

2007, Abalo *et al.* improved the diagonal model further and divided it into four quadrants [23]. Attributes above the diagonal line are categorized into ‘concentrate here’ region. Regions below the diagonal line are further divided based on the midpoint of importance and performance scale: ‘low priority’ for the low performance region, ‘keep up the work’ for the high performance and high importance region, and ‘possible overkill’ for the high performance and low importance region. Building on these findings, the IPA grid modified by Abalo *et al.* was applied for this analysis (Figure 2B). IPSS score of each symptom was used for performance on the horizontal axis. Regression coefficients from a multiple regression analysis were used as indirect importance in the vertical axis [24, 25]. Regression coefficient calculated from a multiple regression analysis between each LUTS score and uQoL score was utilized as the measure of importance. LUTS situated above the diagonal line were considered candidate LUTS for intensive improvement to enhance uQoL, as their importance level exceeded their corresponding performance rating.


### Statistical analysis

Urinary QoL scores were compared pre-implantation and at each post-implantation time point using Wilcoxon rank-sum test to identify the period of uQoL post-implantation deterioration. The afore-mentioned IPAs were conducted pre-implantation, during periods of uQoL declining, and during periods of uQoL improving. Univariate analysis (UVA) of the association between each of the seven LUTS scores and each factor was performed using Student’s *t*-test or simple regression analysis, as appropriate. Statistical significance was set at  $p < 0.05$ , and all variables demonstrating statistical significance in UVA were selected and incorporated into multivariate analysis

**A**



**B**



**Fig. 2.** The original partition of the importance–performance analysis (IPA) grid advocated by Martilla and James (A), and the modified partition of the IPA grid according to Abalo *et al.* used in this study (B)

(MVA) using multiple regression analysis. LUTS scores during periods of uQoL deteriorating were summed for each patient, and utilized as an objective variable in UVA and MVA. Receiver operating characteristic (ROC) curve analysis was performed using dosimetric parameters significantly related to LUTS score to predict an average score of  $\geq 3$ . Cut-off values were determined with Youden's index [26]. All statistical analyses were performed using EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [27].

## Results

### Clinico-pathological characteristics of patients

Table 1 presents patient characteristics. Among 268 patients screened initially, 75 were lost to follow-up within 1 year, and were excluded from the analysis. A total of 193 patients were included in the analysis. The median age of the participants was 68 years (range,

**Table 1.** Patient characteristics (N = 193)


Variable	Value
Age (years), median (range)	68 (50-80)
Follow-up period (months), median (range)	30 (12-120)
Pre-implant prostate volume (cc)	19.36 (8.3-45.0)
Initial PSA (ng/ml), median (range)	6.299 (1.567-18.900)
Clinical T stage (UICC 8th), n (%)	
T1c	75 (38.9)
T2a	99 (51.3)
T2b	19 (9.8)
Gleason score, n (%)	
$\leq 3 + 3$	89 (46.1)
3 + 4	71 (36.8)
4 + 3	33 (17.1)
D'Amico risk classification, n (%)	
Low	70 (36.3)
Intermediate	123 (63.7)
Neoadjuvant hormonal therapy, n (%)	
No	52 (26.9)
Yes	141 (73.1)
Post-implant dosimetry, median (range)	
Prostate D <sub>90</sub> (Gy)	168.72 (104.69-212.72)
Prostate V <sub>100</sub> (%)	97.05 (79.47-99.91)
Prostate V <sub>150</sub> (%)	57.28 (28.62-87.91)
Urethral V <sub>150</sub> (cc)	0.048 (0.000-0.554)
Urethral V <sub>200</sub> (cc)	0.000 (0.000-0.190)
Urethral D <sub>5</sub> (Gy)	223.56 (164.22-422.24)
Urethral D <sub>10</sub> (Gy)	241.57 (161.10-402.67)
Urethral D <sub>30</sub> (Gy)	198.36 (144.00-291.80)
Urethral D <sub>90</sub> (Gy)	147.43 (60.23-232.87)

UICC – Union for International Cancer Control, D<sub>xx</sub> – dose covering xx% of the organ volume, V<sub>xx</sub> – the organ receiving xx% of the dose

50-80 years), and the median follow-up period after implantation was 30 months (range, 12-120 months; 142, 19, and 32 patients were followed up for  $\geq 24$ , 18, and 12 months, respectively). According to D'Amico risk classification, seventy patients had low-risk disease, whereas 123 patients had intermediate-risk disease.

### Longitudinal changes in LUTS and uQoL

Figure 3 presents longitudinal changes in IPSS and uQoL scores. IPSS exhibited a significant increase from the baseline (BL) value at 1 month post-implantation (mean score, 15.9 vs. 6.8 [BL];  $p < 0.001$ ); however, it re-



**Fig. 3.** Longitudinal changes in the mean international prostate symptom score (IPSS) (A), and the 7-grade urinary quality of life (uQoL) score (B). \*Statistically significant ( $p < 0.05$ ); comparison with baseline (BL) values was performed using Wilcoxon signed-rank test

turned to the BL value by 18 months post-implantation (mean, 7.3 vs. 6.8 [BL];  $p = 0.380$ ). The uQoL score reached its highest level at 1 month post-implantation (mean: 3.6 vs. 2.3 [BL],  $p < 0.001$ ), and returned to the BL value by 12 months post-implantation (mean: 2.5 vs. 2.3 [BL];  $p = 0.077$ ). The IPSS and uQoL scores showed similar trends, increasing significantly from the BL values at 1 month post-implantation and then gradually returning to the BL values.


### Importance-performance analysis

Importance-performance analysis was conducted across three time periods, such as pre-implantation, 1-9 months post-implantation during uQoL deterioration, and 12-24 months post-implantation during uQoL improvement (Figure 4). LUTS, including frequency, noc-

turia, and weak stream were targeted for intensive improvement across all the time periods. In addition, incomplete emptying was targeted for intensive improvement pre-implantation. The performance of frequency and weak stream decreased noticeably during the period of uQoL deterioration, whereas their importance increased noticeably. The performance of weak stream improved during the period of uQoL improvement; however, the importance remained high. In contrast, the performance of frequency did not improve during the period of uQoL improvement, but its importance decreased.

### Identification of factors associated with LUTS scores

Table 2 presents results of UVA and MVA comparing LUTS scores during the period of uQoL deterioration



**Fig. 4.** Importance-performance analysis performed during three time periods: pre-implantation (A), 1-9 months post-implantation (B), and 12-24 months post-implantation (C)



Table 2. Association of each lower urinary tract symptom score with each factor

Variable	Concentrate here				Keep up the work				Possible overkill			
	Frequency		Nocturia		Weak stream		Incomplete emptying		Urgency		Intermittency	
Explanatory variables	UVA	MVA	UVA	MVA	UVA	MVA	UVA	MVA	UVA	MVA	UVA	MVA
Age (years)	0.616	–	< 0.001*	Excluded	0.215	–	0.784	–	<b>0.014*</b>	Excluded	0.369	–
Hormone therapy	0.425	–	0.152	–	0.322	–	0.467	–	0.287	–	0.066	–
Baseline value	< 0.001*	< 0.001*	< 0.001*	< 0.001*	< 0.001*	< 0.001*	< 0.001*	< 0.001*	< 0.001*	< 0.001*	< 0.001*	< 0.001*
Prostate volume (cc)	<b>0.015*</b>	<b>0.028*</b>	0.279	–	0.132	–	<b>0.009*</b>	<b>0.009*</b>	<b>0.004*</b>	<b>0.002*</b>	<b>0.002*</b>	<b>0.001*</b>
Prostate D <sub>90</sub> (Gy)	<b>0.006*</b>	0.132	0.849	–	<b>0.003*</b>	<b>0.032*</b>	0.237	–	0.077	–	<b>0.007*</b>	<b>0.029*</b>
Prostate V <sub>100</sub> (%)	<b>0.026*</b>	0.488	0.642	–	<b>0.043*</b>	0.253	0.166	–	0.213	–	0.067	–
Prostate V <sub>150</sub> (%)	0.059	–	0.653	–	0.065	–	0.141	–	0.145	–	<b>0.039*</b>	0.455
Urethral V <sub>150</sub> (cc)	0.653	–	0.600	–	0.358	–	0.801	–	0.360	–	0.788	–
Urethral V <sub>200</sub> (cc)	0.162	–	0.281	–	0.520	–	0.140	–	0.184	–	0.095	–
Urethral D <sub>5</sub> (Gy)	0.196	–	0.740	–	0.803	–	0.154	–	0.330	–	0.087	–
Urethral D <sub>10</sub> (Gy)	0.138	–	0.746	–	0.513	–	0.113	–	0.215	–	<b>0.047*</b>	0.568
Urethral D <sub>30</sub> (Gy)	0.882	–	0.781	–	0.689	–	0.824	–	0.518	–	0.772	–
Urethral D <sub>90</sub> (Gy)	0.102	–	0.442	–	<b>0.012*</b>	0.178	0.234	–	0.066	–	<b>0.003*</b>	<b>0.042*</b>

UVA – univariate analysis, MVA – multivariate analysis, D<sub>xx</sub> – dose covering xx% of the organ volume, V<sub>xx</sub> – the organ receiving xx% of the dose, \* statistically significant; objective variables – combined scores at 1, 3, 6, and 9 months post-implantation (i.e., the urinary quality of life deterioration period)

with clinical and dosimetric factors. As the uQoL scores were at their lowest in 1-9 months post-implantation (Figure 3), each LUTS score was summed during these periods and used as an objective variable. Each LUTS score and its BL value were significantly associated in MVA (each  $p < 0.001$ , positive correlation). LUTS, such as frequency, incomplete emptying, urgency, and straining scores were significantly associated with the prostate volume ( $p = 0.028, 0.009, 0.002$ , and  $0.005$ , respectively, positive correlation). The weak stream score was associated with D<sub>90</sub> ( $p = 0.032$ , positive correlation), whereas the intermittency score was associated with uD<sub>90</sub> ( $p = 0.042$ , positive correlation).


#### Identification of dosimetric cut-off values for prediction of $\geq 3$ average score

ROC curve analysis was applied to predict average score of  $\geq 3$  for each LUTS score during the period of uQoL deterioration (Figure 5). The cut-off value for D<sub>90</sub>, predicting an average score of  $\geq 3$  for weak stream, was 167.01 Gy (specificity, 0.541; sensitivity, 0.690), yielding an area under the curve (AUC) of 0.641 (95% CI: 0.56-0.721%). The cut-off value for uD<sub>90</sub>, predicting an average score of  $\geq 3$  for intermittency, was 136.84 Gy (specificity, 0.407; sensitivity, 0.833), resulting in an AUC of 0.657 (95% CI: 0.57-0.745%).

#### Discussion

This study revealed that a period of 1-9 months after LDR-BT for prostate cancer is the period, in which the uQoL score deteriorates, and LUTS, such as frequency, nocturia, and weak stream should be considered intensively to improve uQoL scores during this period. The LUTS scores tend to increase mainly in patients with low BL scores or large prostate volume. D<sub>90</sub> and uD<sub>90</sub> are associated with frequency and intermittency, respectively, and should not exceed 167.01 Gy and 136.84 Gy, respectively, to prevent significant deterioration in LUTS.

Studies on longitudinal changes in the IPSS and uQoL scores after LDR-BT reported that IPSS returned to the BL value after 12-36 months [5-8, 28, 29], and uQoL returned to the BL value after 12 months [5, 7, 8], which is consistent with the results of the present study. Frequency, nocturia, and weak stream were LUTS to be improved in IPA at any phase. In addition, incomplete emptying was also an important LUTS to be improved pre-implantation. Among the seven LUTS, nocturia, incomplete emptying [30-32], frequency [31], and weak stream [32] were shown to be associated with worse uQoL, although these studies did not focus specifically on patients who underwent radiation therapy for prostate cancer. These four LUTS are consistent with the 'concentrate here' symptoms in the pre-implantation IPA. The importance of weak stream increased in the period of uQoL deterioration (1-9 months); however, the performance of weak stream decreased noticeably. During the uQoL improvement period (12-24 months), the performance of frequency remained low, but its importance decreased. In other words, the symptoms to be focused on for improvement



**Fig. 5.** Receiver operating characteristic curve of D<sub>90</sub> for the prediction of an average weak stream score of ≥ 3 (**A**), and uD<sub>90</sub> for the prediction of an average intermittency score of ≥ 3 (**B**). D<sub>90</sub> – dose covering 90% of the prostate, uD<sub>90</sub> – dose covering 90% of the urethra, AUC – area under curve, \* cut-off point (specificity, sensitivity)

vary in each phase, so an approach tailored to each phase is required. Yoshimura *et al.* reported that weak stream, incomplete emptying, and nocturia were associated with worse uQoL in Japanese patients with benign prostatic hyperplasia (BPH) [32]. Although newly diagnosed patients with BPH suffered from frequency, urgency had the strongest impact on uQoL in pre-operative patients with BPH [32]. In a French community-based study, urgency was the most bothersome LUTS [33]. This may be due to the differences in study populations, ethnicity, or cultural differences.

An association was observed between D<sub>90</sub> and weak stream during the uQoL deterioration period, and the cut-off value was 167.01 Gy in the present analysis. Stock *et al.* reported that D<sub>90</sub> > 180 Gy was associated with increased urinary symptoms [34]. Tanimoto *et al.* reported that V<sub>100</sub> of the prostate was linked to urinary toxicities [7]. Although prostate treatment intensity and dose coverage are associated with urinary toxicities, a significant reduction in biochemical recurrence has also been reported after receiving prostate D<sub>90</sub> > 180 Gy [35, 36]. Stock *et al.* suggested that optimal <sup>125</sup>I prostate implants should deliver a D<sub>90</sub> of 140–180 Gy to balance urinary toxicity and biochemical recurrence [34]. In the present study, an association was observed between uD<sub>90</sub> and the intermittency score during the period of uQoL deterioration. UD<sub>90</sub> has been reported to be associated with IPSS increment [29] and urinary toxicities [37]. Furthermore, uD<sub>90</sub> is associated with obstructive urination among LUTS [38]. Intermittency is a symptom of 'possible overkill' in IPA; therefore, little improvement in uQoL can be achieved by maintaining uD<sub>90</sub> below 136.84 Gy. However, it is also associated with weak stream in UVA that may lead to lower weak stream scores and improved uQoL.

Recent systematic reviews have shown that α1-blockers improve LUTS and uQoL after brachytherapy [39]. However, all patients started receiving them internally immediately post-implantation.

Other approaches, such as adequately considering patient's LUTS during consultation, empathic attitude, and positive approach (being positive about the problem and when it would settle) may lead to improved patient satisfaction, i.e., better uQoL [40]. Adequate patient education about the causes of symptoms and effects of alcohol and caffeine intake is also important to improve LUTS and uQoL [41, 42].

The present study is limited by its retrospective design. IPSS was calculated based on the frequency of each symptom, with a maximum score of 5 for each symptom. Patients with a high frequency of pre-implantation symptoms will already have a maximum score of 5; therefore, post-implantation evaluation may not capture potential worsening of symptoms. As a potential solution, IPSS evaluations should be conducted using a visual analog scale in the future [31]. In addition, patients who declined to complete the IPSS questionnaire or were subsequently followed up at a different institution within 1 year of post-implantation were excluded from this study, potentially introducing selection bias. It is important to note that such bias may have affected the study results, as patients with more severe symptoms could have been more willing to complete the questionnaire, whereas those with no or mild symptoms may have opted for follow-up at a nearby facility. Furthermore, D<sub>90</sub> and uD<sub>90</sub> were evaluated as predictors for weak stream and intermittency scores using ROC curves. However, the obtained AUC values were 0.641 and 0.657, indicating limited predictive capability. These modest AUC values highlight the lim-

itations of  $D_{90}$  and  $uD_{90}$  as standalone dosimetric predictors, suggesting the need for further research to identify stronger dosimetric predictors.

## Conclusions

In conclusion, this study utilized IPA during the period of uQoL deterioration (1-9 months) after LDR-BT for prostate cancer to prioritize LUTS improvement in prostate cancer patients based on performance and importance ratings. Frequency, nocturia, and weak stream were identified as the priority areas for improvement during the period of uQoL deterioration. The factors associated with these symptom scores were also identified. As for the dosimetric factors, LUTS, such as weak stream and intermittency were associated with  $D_{90}$  and  $uD_{90}$ , respectively. The results of this analysis can be used to prioritize LUTS that need to be improved in daily medical care. The results of this analysis can be used to plan treatment with a greater awareness of uQoL following LDR-BT, thus helping patients and healthcare professionals to determine goals.

## Acknowledgements

The authors would like to thank all the staff of the radiotherapy department, all the urologists at our institution, and all the patients who participated in the study for their understanding and support. We would also like to thank Editage ([www.editage.com](http://www.editage.com)) for English language editing.

## Disclosure

The authors report no conflict of interest.

## References

1. NCCN Guidelines Version 1.2023 Prostate Cancer. Available at <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459> (accessed February 20, 2023).
2. EAU Guideline for Prostate Cancer. Available at <https://uroweb.org/guidelines/prostate-cancer> (accessed December 3, 2023).
3. Barry MJ, Fowler FJ, O'Leary MP et al. The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. *Urol J* 1992; 148: 1549-1557.
4. Onishi K, Tanaka N, Miyake M et al. Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer. *Clin Transl Radiat Oncol* 2019; 14: 51-58.
5. Tanaka N, Fujimoto K, Hirao Y et al. Variations in International Prostate Symptom Scores, uroflowmetric parameters, and prostate volume after 125I permanent brachytherapy for localized prostate cancer. *Urology* 2009; 74: 407-411.
6. Miyake M, Tanaka N, Asakawa I et al. Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute. *BMC Urol* 2017; 17: 62.
7. Tanimoto R, Bekku K, Katayama N et al. Predictive factors for acute and late urinary toxicity after permanent interstitial brachytherapy in Japanese patients. *Int J Urol* 2013; 20: 812-817.
8. Iinuma K, Nakano M, Kato T et al. Assessment of long-term changes in lower urinary tract symptoms in patients with prostate cancer who underwent low-dose-rate prostate brachytherapy. *Urology* 2020; 142: 213-220.
9. Tremblay G, Nguyen TA, Marolleau J et al. Impact of age on the Quadrella index assessing oncological and functional results after prostate brachytherapy: A 6-year analysis. *J Contemp Brachytherapy* 2023; 15: 89-95.
10. Zuber S, Weiß S, Baaske D et al. Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review. *Radiat Oncol* 2015; 10: 49.
11. Hoffman KE, Penson DF, Zhao Z et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. *JAMA* 2020; 323: 149-163.
12. Martilla JA, James JC. Importance-performance analysis. *J Mark* 1977; 41: 77-79.
13. Nayfeh A, Yarnell CJ, Dale C et al. Evaluating satisfaction with the quality and provision of end-of-life care for patients from diverse ethnocultural backgrounds. *BMC Palliat Care* 2021; 20: 145.
14. Hay CC, Pappadis MR, Sander AM et al. Important-performance analysis to conceptualize goal priorities in community dwelling stroke survivors. *Top Stroke Rehabil* 2022; 29: 310-320.
15. Sakurai T, Takamatsu S, Shibata S et al. Incidence and dosimetric predictive factors of late rectal toxicity after low-dose-rate brachytherapy combined with volumetric modulated arc therapy in high-risk prostate cancer at a single institution: Retrospective study. *Brachytherapy* 2021; 20: 584-594.
16. Stock RG, Stone NN, Wesson MF et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. *Int J Radiat Oncol Biol Phys* 1995; 32: 219-225.
17. Ormanović Š, Čirić A, Talović M et al. Importance-performance analysis: Different approaches. *Acta Kinesiológica* 2017; 11: 58-66.
18. Chen JK. A new approach for diagonal line model of Importance-Performance Analysis: a case study of tourist satisfaction in China. *Sage Open* 2021; 11: 1-11.
19. Levenburg NM, Magal SR. Applying Importance-Performance Analysis to evaluate e-business strategies among small firms. *e-Service Journal* 2004; 3: 29.
20. Nale RD, Rauch DA, Wathen SA et al. An exploratory look at the use of importance-performance analysis as a curricular assessment tool in a school of business. *J Workplace Learn* 2000; 12: 139-145.
21. Slack N. The importance-performance matrix as a determinant of improvement priority. *Int J Oper Prod Manag* 1994; 14: 59-75.
22. Bacon DR. A comparison of approaches to Importance-Performance Analysis. *Int J Mark Res* 2003; 45: 1-15.
23. Abalo J, Varela J, Manzano V. Importance values for Importance-Performance Analysis: A formula for spreading out values derived from preference rankings. *J Bus Res* 2007; 60: 115-121.
24. Matzler K, Bailom F, Hinterhuber HH et al. The asymmetric relationship between attribute-level performance and overall customer satisfaction: a reconsideration of the importance-performance analysis. *Ind Mark Manag* 2004; 33: 271-277.
25. Matzler K, Sauerwein E. The factor structure of customer satisfaction. *Int J Serv Ind Manag* 2002; 13: 314-332.
26. Youden WJ. Index for rating diagnostic tests. *Cancer* 1950; 3: 32-35.
27. Kanda Y. Investigation of the freely available easy-to-use software 'EZ' for medical statistics. *Bone Marrow Transplant* 2013; 48: 452-458.
28. Ohashi T, Yoroze A, Toya K et al. Serial changes of International Prostate Symptom Score following I-125 prostate brachytherapy. *Int J Clin Oncol* 2006; 11: 320-325.



29. Murakami N, Itami J, Okuma K et al. Urethral dose and increment of International Prostate Symptom Score (IPSS) in transperineal permanent interstitial implant (TPI) of prostate cancer. *Strahlenther Onkol* 2008; 184: 515-519.
30. Batista-Miranda JE, Molinuevo B, Pardo Y. Impact of lower urinary tract symptoms on quality of life using functional assessment cancer therapy scale. *Urology* 2007; 69: 285-288.
31. Ushijima S, Ukimura O, Okihara K et al. Visual analog scale questionnaire to assess quality of life specific to each symptom of the International Prostate Symptom Score. *Urol J* 2006; 176: 665-671.
32. Yoshimura K, Arai Y, Ichioka K et al. Symptom-specific quality of life in patients with benign prostatic hyperplasia. *Int J Urol* 2002; 9: 485-490.
33. Sagnier PP, MacFarlane G, Teillac P et al. Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. *Urol J* 1995; 153: 669-673.
34. Stock RG, Stone NN, Dahlal M et al. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. *Brachytherapy* 2002; 1: 83-89.
35. Kao J, Stone NN, Lavaf A et al. 125I Monotherapy using D90 implant doses of 180 Gy or greater. *Int J Radiat Oncol Biol Phys* 2008; 70: 96-101.
36. Gómez-Iturriaga Piña A, Crook J, Borg J et al. Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with D90  $\geq$ 180 Gy. *Int J Radiat Oncol Biol Phys* 2010; 78: 422-427.
37. Ohga S, Nakamura K, Shioyama Y et al. Acute urinary morbidity after a permanent 125I implantation for localized prostate cancer. *J Radiat Res* 2014; 55: 1178-1183.
38. Kragelj B. Obstructive urination problems after high-dose-rate brachytherapy boost treatment for prostate cancer are avoidable. *Radiol Oncol* 2016; 50: 94-103.
39. King MT, Keyes M, Frank SJ et al. Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systematic review and executive summary of an evidence-based consensus statement. *Brachytherapy* 2021; 20: 1114-1129.
40. Little P, Everitt H, Williamson I et al. Observational study of effect of patient centredness and positive approach on outcomes of general practice consultations. *BMJ* 2001; 323: 908-911.
41. Bryant CM, Dowell CJ, Fairbrother G. Caffeine reduction education to improve urinary symptoms. *Br J Nurs* 2002; 11: 560-565.
42. Bradley CS, Erickson BA, Messersmith EE et al. Evidence of the impact of diet, fluid intake, caffeine, alcohol and tobacco on lower urinary tract symptoms: A systematic review. *Urol J* 2017; 198: 1010-1020.